Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16189993 | 0.88 | PTGS2 (0.39) | PTGS2PKMTHRB | |
| SCHEMBL1106452 | 0.77 | PTGS2 (0.39) | PTGS2PKMMGLLMAPTPOLB | |
| SCHEMBL10282152 | 0.75 | PTGS2 (0.38) | PTGS2MGLL | |
| SCHEMBL1106501 | 0.75 | PTGS2 (0.38) | PTGS2PKMMEN1KMT2AMGLL | |
| SCHEMBL9453847 | 0.75 | PTGS2 (0.41) | PTGS2MEN1KMT2AMAPTPOLB | |
| SCHEMBL1106507 | 0.75 | PTGS2 (0.49) | PTGS2MGLLHTR2C | |
| SCHEMBL15803906 | 0.75 | PTGS2 (0.38) | PTGS2MEN1KMT2AMAPTPIM1 | |
| SCHEMBL13431756 | 0.75 | OPRM1 (0.39) | PTGS2MEN1KMT2AMAPTHTR2A | |
| SCHEMBL25911755 | 0.74 | FEN1 (0.34) | THRBMEN1KMT2AMAPTPOLB | |
| SCHEMBL13848501 | 0.73 | PTGS2 (0.45) | PTGS2MEN1KMT2AMGLLPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
| US-20240217951-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-04 | — | — | US | disclosed |
| WO-2024126773-A1 | IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| CN-117886801-B | Pyridone pyrimidine CDK inhibitor, and preparation method and application thereof | 中国药科大学 | 2024-05-17 | — | — | CN | disclosed |
| CN-117886801-A | Pyridone pyrimidine CDK inhibitor, and preparation method and application thereof | 中国药科大学 | 2024-04-16 | — | — | CN | disclosed |
| WO-2014169845-A2 | 4,5-DIHYDRO-PYRAZOLO [3, 4-C] PYRID-2-ONES, PREPARATION METHOD AND APPLICATION THEREOF | 四川海思科制药有限公司 (CN) | 2014-10-23 | — | — | WO | disclosed |
| US-8742120-B2 | Methods of preparing factor xa inhibitors and salts thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8377974-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377974-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-8153670-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153670-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110152530-A1 | METHODS OF PREPARING FACTOR XA INHIBITORS AND SALTS THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2011-06-23 | — | — | US | disclosed |
| US-20110152530-A1 | METHODS OF PREPARING FACTOR XA INHIBITORS AND SALTS THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2011-06-23 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298806-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | PTGS2 1023/4885PKM 2122/4885PGR 1535/4885 |
| US-20110152530-A1 | METHODS OF PREPARING FACTOR XA INHIBITORS AND SALTS THEREOF | F12, TFPI, F11 | PTGS2 2431/4885PKM 2663/4885PGR 3351/4885 |
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | PTGS2 4143/4885PKM 2782/4885PGR 2811/4885 |
| US-20240217951-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | PTGS2 4357/4885PKM 3093/4885PGR 3290/4885 |
| US-20120178733-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | PTGS2 1023/4885PKM 2122/4885PGR 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.